Prescribing Antidepressants for Elite Athletes: Is There Evidence to Support Best Practices in Sports Psychiatry? A Scoping Review.

IF 6.2 2区 医学 Q1 SPORT SCIENCES
Rafael Zini, João Maurício Castaldelli-Maia, Malte Christian Claussen, Maria Olivia Pozzolo Pedro, Renner Santos Borges, André Furtado de Ayalla Rodrigues, Lara Ferreira Camacho, Gustavo Bonini Castellana
{"title":"Prescribing Antidepressants for Elite Athletes: Is There Evidence to Support Best Practices in Sports Psychiatry? A Scoping Review.","authors":"Rafael Zini, João Maurício Castaldelli-Maia, Malte Christian Claussen, Maria Olivia Pozzolo Pedro, Renner Santos Borges, André Furtado de Ayalla Rodrigues, Lara Ferreira Camacho, Gustavo Bonini Castellana","doi":"10.1186/s40798-026-01010-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Elite athletes face unique mental health challenges, yet the use of antidepressants in this population remains underresearched. Despite the prevalence of depressive and anxiety symptoms, there are no specific pharmacological guidelines tailored to athletes' mental health needs or performance demands.</p><p><strong>Objective: </strong>This scoping review aimed to explore the current literature on the use of antidepressant medications among elite athletes with symptoms of or who were diagnosed with depressive or anxiety disorders, focusing on treatment effectiveness, safety, performance, and, mainly, the athlete's well-being.</p><p><strong>Methods: </strong>A systematic search of PubMed, Embase, and PsycINFO (February 18-20, 2025) was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Scoping Reviews (PRISMA-ScR) guidelines. Predefined terms related to athletes, antidepressants, and psychiatric disorders were employed. Studies were included if they involved elite athletes treated with antidepressants for major depressive disorder, bipolar depression, or generalized anxiety disorder. The data were charted and narratively synthesized.</p><p><strong>Results: </strong>Among the 34,131 records screened, 15 met the inclusion criteria: 11 narrative reviews, 2 systematic reviews, 1 survey, and 1 position statement. Most studies provide recommendations on the basis of the general population, offering limited data on elite athletes with formal diagnoses. Few studies have reported treatment durations or mental health outcomes. While performance effects have been emphasized, psychological recovery is rarely addressed. Selective serotonin reuptake inhibitors-particularly escitalopram, fluoxetine, and sertraline-were the most commonly suggested drugs.</p><p><strong>Conclusion: </strong>There is a lack of robust evidence to guide antidepressant use among elite athletes. Future research should prioritize trials involving clinically diagnosed athletes, structured protocols, and outcomes centered on mental health and well-being rather than merely performance.</p>","PeriodicalId":21788,"journal":{"name":"Sports Medicine - Open","volume":"12 1","pages":""},"PeriodicalIF":6.2000,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13319284/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sports Medicine - Open","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40798-026-01010-3","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SPORT SCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Elite athletes face unique mental health challenges, yet the use of antidepressants in this population remains underresearched. Despite the prevalence of depressive and anxiety symptoms, there are no specific pharmacological guidelines tailored to athletes' mental health needs or performance demands.

Objective: This scoping review aimed to explore the current literature on the use of antidepressant medications among elite athletes with symptoms of or who were diagnosed with depressive or anxiety disorders, focusing on treatment effectiveness, safety, performance, and, mainly, the athlete's well-being.

Methods: A systematic search of PubMed, Embase, and PsycINFO (February 18-20, 2025) was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Scoping Reviews (PRISMA-ScR) guidelines. Predefined terms related to athletes, antidepressants, and psychiatric disorders were employed. Studies were included if they involved elite athletes treated with antidepressants for major depressive disorder, bipolar depression, or generalized anxiety disorder. The data were charted and narratively synthesized.

Results: Among the 34,131 records screened, 15 met the inclusion criteria: 11 narrative reviews, 2 systematic reviews, 1 survey, and 1 position statement. Most studies provide recommendations on the basis of the general population, offering limited data on elite athletes with formal diagnoses. Few studies have reported treatment durations or mental health outcomes. While performance effects have been emphasized, psychological recovery is rarely addressed. Selective serotonin reuptake inhibitors-particularly escitalopram, fluoxetine, and sertraline-were the most commonly suggested drugs.

Conclusion: There is a lack of robust evidence to guide antidepressant use among elite athletes. Future research should prioritize trials involving clinically diagnosed athletes, structured protocols, and outcomes centered on mental health and well-being rather than merely performance.

给优秀运动员开抗抑郁药:有证据支持运动精神病学的最佳实践吗?范围审查。
背景:优秀运动员面临着独特的心理健康挑战,然而在这一人群中使用抗抑郁药的研究仍然不足。尽管抑郁和焦虑症状普遍存在,但没有专门针对运动员心理健康需求或表现要求的药理学指南。目的:本综述旨在探讨目前关于有抑郁或焦虑症症状或被诊断为抑郁或焦虑症的优秀运动员使用抗抑郁药物的文献,重点关注治疗的有效性、安全性、表现,主要是运动员的健康状况。方法:系统检索PubMed、Embase和PsycINFO(2025年2月18日至20日),按照系统评价和meta分析范围评价(PRISMA-ScR)指南的首选报告项目进行。使用了与运动员、抗抑郁药和精神疾病相关的预定义术语。如果研究涉及接受抗抑郁药治疗重度抑郁症、双相抑郁症或广泛性焦虑症的优秀运动员,则纳入研究。这些数据被制成图表并以叙述的方式加以综合。结果:在筛选的34131条记录中,15条符合纳入标准:11篇叙述性评价,2篇系统评价,1篇调查性评价,1篇立场陈述。大多数研究提供的建议是基于一般人群,提供的关于正式诊断的优秀运动员的有限数据。很少有研究报告治疗持续时间或心理健康结果。虽然强调了表现的影响,但很少涉及心理恢复。选择性血清素再摄取抑制剂——尤其是艾司西酞普兰、氟西汀和舍曲林——是最常被推荐的药物。结论:缺乏强有力的证据来指导优秀运动员使用抗抑郁药。未来的研究应该优先考虑临床诊断运动员的试验,结构化的方案,以及以心理健康和福祉为中心的结果,而不仅仅是表现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Sports Medicine - Open
Sports Medicine - Open SPORT SCIENCES-
CiteScore
7.00
自引率
4.30%
发文量
142
审稿时长
13 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书